Deltec Asset Management’s Adicet Bio ACET Stock Holding History

Deltec Asset Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-690	Closed	-$789K	–	166
2019 Q2	$789K	Sell	690 -3,156	-82%	-$2.86M	0.17%	102
2019 Q1	$2.94M	Buy	3,846 +1,492	+63%	+$1.36M	0.64%	41
2018 Q4	$2.27M	Sell	2,354 -1,300	-36%	-$1.71M	0.63%	40
2018 Q3	$6.2M	Buy	3,654 +1,206	+49%	+$1.57M	1.19%	26
2018 Q2	$2.51M	Buy	+2,448	New	+$2.64M	0.51%	53

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deltec Asset Management's ACET Position: Q3 2019 in Review

Deltec Asset Management sold out of Adicet Bio (ACET) in Q3 2019, closing a stake of 690 shares — an estimated $789K sold.

Deltec Asset Management first reported a position in ACET in Q2 2018 and held it in 5 quarters. The position peaked at $6.2M in Q3 2018. 56 funds tracked by Wall St. Rank hold ACET as of Q3 2019.

Deltec Asset Management reported no remaining Adicet Bio position as of Q3 2019 after selling out during the quarter.
Deltec Asset Management sold 690 Adicet Bio shares in Q3 2019, an estimated $789K.
Deltec Asset Management first reported a position in Adicet Bio in Q2 2018 and held it in 5 quarters.
Deltec Asset Management's Adicet Bio position peaked at $6.2M in Q3 2018.
56 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2019.

Based on Deltec Asset Management's 13F filing for Q3 2019, filed 24 Oct 2019.